The objective of this study was to describe the outcome of allogeneic stem cell transplantation (alloSCT) in a series of patients with B cell chronic lymphocytic leukemia (B-CLL). Twenty-three B-CLL patients were transplanted between 1988 and 1997 using stem cells from a related (n = 20) or an unrelated donor (n = 3). The median age of the patients was 46 years, and the median number of prior chemotherapy regimens received was two. At transplantation, 14 patients had chemorefractory disease and 12 of these were refractory to fludarabine. The preparative regimens included total body irradiation (TBI) in 22 of the 23 cases. All patients received graft-versus-host disease (GVHD) prophylaxis with cyclosporine and methotrexate. Twenty patients (87%) achieved a complete remission (CR). The incidence of grade II-IV acute GVHD was 54%. Fourteen (61%) patients are alive and disease-free, including two with unrelated donors, at a median of 26 months (range, 9-115 months). Nine patients (39%) have died, one of whom had progressive B-CLL. The only favorable prognostic factor for failure-free survival (FFS) and overall survival (OS) after alloSCT was the use of a cyclophosphamide/TBI rather than an etoposide/ cyclophosphamide/TBI regimen (P = 0.03). The projected 5-year FFS, OS, and relapse rates after alloSCT were 65% (95% CI, 48-88%), 62% (95% CI, 43-88%), and 5% (95%, CI 0-13%), respectively. These findings demonstrate the potential of high-dose therapy and alloSCT for inducing and maintaining a remission in patients with advanced or chemorefractory B-CLL. The low relapse rate may be due to an allogeneic graft-versus-leukemia effect. Bone Marrow Transplantation (2000) 25, 717-722.
B cell chronic lymphocytic leukemia (B-CLL) is considered incurable with conventional chemotherapy. 1 Patients with B-CLL who relapse after first-line treatment have an average survival of 9 to 29 months. 2 At the time of diagnosis, 40% of B-CLL patients are less than 60 years of age, and 10% are younger than 50 years. 3 Palliative chemotherapy is not a satisfactory treatment for younger individuals with B-CLL and therefore these patients are potential candidates for hematopoietic stem cell transplant (SCT). However, relatively few transplants have been performed in B-CLL because of concerns about transplantrelated toxicity in a disease that frequently has an indolent course. Improvements in the safety of SCT have encouraged some investigators to initiate pilot studies of SCT for younger patients with poor-prognosis B-CLL. [4] [5] [6] [7] [8] [9] [10] [11] [12] The results of these early reports suggest that high-dose therapy followed by autologous hematopoietic stem cell transplantation (autoSCT) does not eradicate B-CLL, and most patients will relapse. [4] [5] [6] Allogeneic stem cell transplantation (alloSCT) offers the benefits of high-dose therapy, a tumorfree graft, and the potential for an immunologically mediated graft-versus-leukemia (GVL) effect. 7 Other types of leukemia have been cured following alloSCT and a few early reports have suggested promising results for young patients with advanced B-CLL. [8] [9] [10] [11] [12] This report summarizes the outcome of 23 patients who received alloSCT for recurrent or chemorefractory B-CLL.
Patients and methods

Patients
Between 1988 and 1997, 23 consecutive patients with B-CLL received high-dose therapy and unmanipulated alloSCT. The experience of one patient was previously reported. 13 Fourteen patients were treated at the University of Nebraska Medical Center (UNMC) and nine at the Vanderbilt University Medical Center and Veterans Affairs Medical Center Bone Marrow Transplantation Program in Nashville (VUBMT). Twenty patients received related donor stem cells (13 bone marrow and seven peripheral blood) and three received marrow from an unrelated donor. In three cases, the related donor was serologically mis-matched at one HLA-A or -B locus, one related donor had an additional allelic minor mismatch at HLA-DR4, and two unrelated donors had serological minor-mismatches at the A or B locus. A hematopathologist (DDW) confirmed the diagnosis of B-CLL in all cases. 14 The entry criteria for alloSCT were essentially the same at both institutions. All study subjects had poor-prognostic features including recurrent or chemorefractory disease, advanced stage, and/or diffuse bone marrow involvement. The median age of the patients was 46 years (range, 29-60 years) and the median time between diagnosis and alloSCT was 19 months (range, 4-160 months). The patients had received a median of two prior chemotherapeutic regimens and 14 patients had chemorefractory disease at the time of alloSCT (Table 1 ). All protocols were approved by the local Institutional Review Board and all patients and donors gave informed consent to participate.
Transplantation protocol
The etoposide-containing preparative regimens were as follows: (1) etoposide 1800 mg/m 2 on day −7, followed by cyclophosphamide (CY) 60 mg/kg/day (total 120 mg/kg) on days −6 and −5, and TBI 1200 cGY in six fractions (UNMC); or (2) etoposide 1800 mg/m 2 on day −7, followed by CY 50 mg/kg (total 150 mg/kg) on days −6, −5, −4 and TBI 1000 cGy in five fractions (VUBMT). The cyclophosphamide-TBI regimens were identical in both institutions: ) on days −6 to −3, and carmustine 400 mg/m 2 on day −2). The patients received preparative regimens that were in use at each institution at the time the transplants were performed. No specific criteria were used to determine which patients received etoposide in addition to CY and TBI. Bone marrow was harvested under general anesthesia. Allogeneic blood stem cells were mobilized from healthy donors with recombinant granulocyte colony-stimulating factor (G-CSF; Amgen, Thousand Oaks, CA, USA), collected by apheresis and cryopreserved (one patient received non-cryopreserved blood alloSCT). 15, 16 Day 0 for the recipient was the day of stem cell infusion. Eighteen recipients of related donor grafts received G-CSF post SCT until neutrophil recovery. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and methotrexate. Details of the transplantation protocols and supportive care are reported elsewhere.
15,16
Evaluation and definitions
Neutrophil engraftment was defined as the first of 3 consecutive days with an absolute neutrophil count (ANC) у500/l. Platelet engraftment was defined as the day the platelet count exceeded 20 000/l without a platelet transfusion, and red blood cell (RBC) engraftment was defined as the day of the last RBC transfusion. In some cases where both the donor and the recipient were of the same gender, donor engraftment was confirmed using a molecular DNA fingerprinting technique. 17 GVHD was confirmed by biopsy and graded clinically. 18 Before admission for SCT, the clinical evaluation included a physical examination, complete blood count, chemistry profile, chest and abdominal CT scans, and a bone marrow biopsy and aspiration. National Cancer Institute guidelines were used to evaluate the response to alloSCT.
14 Chemorefractory disease was defined as the absence of at least a partial response following the last pretransplant chemotherapeutic regimen. Remission status was assessed by bone marrow analysis and clinical criteria at 100 days post transplantation. Follow-up assessments were performed every 3 to 6 months. A complete remission (CR) was defined as a circulating lymphocyte count less than 4000/l, less than 30% lymphocytes, absence of morphologically abnormal lymphocytes in the bone marrow, and no lymphadenopathy or hepatosplenomegaly as assessed by clinical examination and computerized tomography. Immunological remission was defined as the absence of abnormal B lymphocytes in the bone marrow using dual immunofluorescence flow cytometry and antibodies against surface CD5, CD19, CD20 and CD23 antigens, and immunoglobulin light chains (Coulter, Miami, FL, USA).
Study design and statistical methods
This is a two-center retrospective cohort analysis. The primary outcomes evaluated were complete remission rate, failure-free survival, overall survival, and relapse rate. All patient characteristics and clinical endpoints were recorded prospectively in standardized transplantation databases. Distribution of time-to-event data was estimated using the Kaplan-Meier method and differences between the groups were assessed using the log-rank test. GVHD incidence rates were compared using Fisher's exact test.
Results
Transplantation and engraftment
The median number of mononuclear cells infused was 2.7 (range, 1.7-17.6) × 10 8 /kg recipient weight. Twenty-two patients achieved stable neutrophil engraftment at a median of 16 days (range, 9-34 days) post SCT. One patient who did not experience neutrophil engraftment died of an aspergillus infection with persistent B-CLL 2 months after transplantation. Sixteen patients achieved platelet transfusion independence at a median of 29 days (range, 11-95 days). Fifteen patients achieved red blood cell transfusion independence at a median of 37 days (range, 5-72 days). One patient (No. 9) who received a two-antigen mismatched (minor on the DRB1 locus) transplant from his daughter experienced full autologous recovery of hematopoiesis confirmed by cytogenetics.
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Response
Twenty patients (87%, 95% CI 68-96%) achieved a complete remission (CR) after alloSCT, and 13 of 14 patients who were evaluated were found to be in an immunological remission by bone marrow flow cytometry. Two patients failed to achieve CR and one was not evaluable for remission status due to early death (Table 2) . One patient (No. 12) was not in remission on day +100. He developed chronic GVHD and repeated evaluations demonstrated a gradual improvement of leukemia. At 24 months, his bone marrow was tumor-negative morphologically and flow cytometry showed no evidence of leukemia. One patient (No. 19) who received marrow from an unrelated donor had persistent bulky lymphadenopathy, lymphocytosis, and massive bone marrow involvement on day +28. After withdrawal of cyclosporine and subsequent development of steroid-responsive grade II acute GVHD of the skin, the tumor load rapidly diminished over a period of 2 weeks. At day +100, he was in clinical CR but not immunological remission. Nine months after alloSCT, he achieved an immunological remission, and conversion to donor-type hematopoiesis was confirmed by bone marrow DNA analysis. No patient received donor leukocyte infusions post SCT.
GVHD
Grade II-IV acute GVHD occurred in 12 of 22 (54%, 95% CI 34-75%) evaluable patients (three grade II, eight grade III and one grade IV). Among 14 patients who received fludarabine prior to transplantation, the incidence of grade II-IV acute GVHD was 57%. This compares with four of eight patients (50%) who never received fludarabine (P = 1.00). There was no difference between patients who received fludarabine and those who did not in terms of the degree of HLA matching. However, the patients not receiving fludarabine were younger (40 years vs 48 years, P = 0.08), which may have resulted in a lower incidence of acute GVHD. Eight patients received fludarabine as the most recent therapy prior to transplantation. One additional patient received a course of cladribine following fludarabine failure. Chronic GVHD occurred in 13 of 19 (68%) evaluable individuals (Table 2) .
Survival and relapse
Fourteen (61%) patients are alive and disease-free at a median of 26 months (range, 9-115 months) following alloSCT. Eight of these 14 patients (57%) had chemorefractory disease ( Table 2 ). Two of the three patients who received marrow from an unrelated donor are alive and in CR at 21 and 43 months post SCT. Nine patients (39%) have died, eight of causes other than relapse. The causes of death in these patients are as follows: one with multiorgan failure, two of aspergillus infection, one of sepsis, one of adenovirus pneumonia, one of ventricular tachycardia 5 years post SCT, and two of acute or chronic GVHD. Only one patient, who relapsed 12 months after transplant, died of progressive B-CLL. The early (100-day) post-SCT mortality was 17%. There was no significant difference in FFS or OS between patients who had chemorefractory vs chemosensitive disease (P = 0.8; Figure 1 ). The following factors were studied in a univariate analysis for their influence on FFS and OS: age (Ͻmedian vs уmedian), gender, time from diagnosis (Ͻmedian vs уmedian), number of prior chemotherapy regimens, Rai stage at transplantation, bone marrow lymphocytes at transplantation (Ͻ30% vs у30%), acute or chronic GVHD, HLA match (mismatch vs fully matched donor), stem cell source (bone marrow vs peripheral blood), mononuclear cell dose (Ͻmedian vs уmedian dose), post-SCT growth factor administration, and type of conditioning regimen (etoposide vs no etoposide). Cytogen- etics, beta-2 microglobulin, and lymphocyte doubling time were not available in a sufficient number of cases to permit inclusion in the analysis. The only prognostic factor suggestive of better FFS and OS was the use of a CY-TBI conditioning regimen as compared with etoposide-CY-TBI (P = 0.03). Whereas none of the six patients who received the CY-TBI regimen died or relapsed post SCT, nine of 16 patients who received the etoposide-CY-TBI regimen subsequently died including one due to recurrent B-CLL. The proportion of chemorefractory patients was not different in these two groups. There were no differences in the mortality rates among the etoposide-CY-TBI-treated patients. The projected 5-year FFS and OS after CY-TBI or etoposide-CY-TBI were 100% vs 49% (95% CI 20-82%) and 100% vs 47% (95% CI 27-82%), respectively ( Figure 2) . The projected 5-year FFS, OS, and the relapse rate for all 23 patients following alloSCT were 65% (95%CI, 48-88%), 62% (95%CI, 43-88%) and 5% (95%CI, 0-13%), respectively.
Discussion
The earliest attempt to treat B-CLL using allogeneic bone marrow transplantation was reported in 1957 by Thomas and coworkers. 19 More extensive experience with alloSCT for B-CLL has begun to accumulate over the last decade. An International Bone Marrow Transplantation Registry report and four single center studies which included a total of 88 patients have demonstrated the ability of high-dose therapy and alloSCT to induce a CR in a majority of patients with advanced or refractory B-CLL. 5, [8] [9] [10] [11] Many of the remissions in these studies were durable according to clinical criteria, as well as when studied with immunological and molecular techniques.
This report confirms the ability of high-dose therapy and alloSCT to produce complete remissions for patients with advanced or refractory B-CLL. Interestingly, in two individuals, a CR was reached only after withdrawal of cyclosporine and the development of acute or chronic GVHD. Others have also reported that B-CLL patients may obtain a CR after withdrawal of immunosuppression or after infusion of donor leukocytes. [20] [21] [22] These observations indicate the presence of an effective allogeneic graft-versusleukemia effect in B-CLL. Only one patient relapsed in the present series, in contrast to the 3-year relapse rate of 56% observed in our prior study of autologous SCT for B-CLL. 4 In addition, all patients undergoing autologous SCT had chemosensitive disease and a minimal tumor burden at the time of transplantation. 4 Relapse rates of up to 70% have been observed after autoSCT for advanced B-CLL, despite the use of bone marrow purging. 6 Whether the high rate of relapse after autoSCT for advanced B-CLL is due to the presence of leukemic cells in the graft or due to the absence of a GVL effect can only be assessed if results from a sufficient number of syngeneic transplants can be compared with alloSCT results.
The projected 5-year overall survival of 62% in this report compares favorably with the survival of similar B-CLL patients who were treated with conventional chemotherapy. 2 The median survival of previously treated, but not chemorefractory, B-CLL patients who received fludarabine as a single agent was only 29 months. In the present study, nine of 12 (75%) fludarabine-refractory patients achieved a CR, and six have remained in CR for 21-43 months (median, 26 months). After conventional salvage chemotherapy, only 2% of fludarabine-refractory patients have been reported to obtain a CR with a median survival of only 8 months. 23 In contrast to low-grade lymphoma, pretransplant chemosensitivity was not a predictor of survival. 24 B-CLL may be more sensitive to allogeneic GVL effect as compared to the low-grade lymphomas. Alternative explaBone Marrow Transplantation nations for our results may relate to the short duration of follow-up or lack of statistical power to demonstrate any influence of chemosensitivity or dose-intensity.
The transplant-related mortality was high in this series and underscores the need to consider alloSCT only in appropriately selected patients who have high-risk B-CLL. Our study was not meant to investigate the possibility of a lower incidence of acute GVHD after treatment with fludarabine, and this important question should be studied in appropriately designed trials. The use of less toxic, nonmyeloablative preparative regimens has been advocated as a way of reducing transplant-related mortality while maintaining the GVL effect. 25 Preliminary data have shown that alloSCT following a non-myeloablative regimen of 200 cGy TBI results in donor engraftment, minimal toxicity, and a potent GVL effect in B-CLL. 26 However, whether such regimens are adequate for patients with large tumor burdens has yet to be determined. 25 T cell-depletion of the graft is another strategy that could be explored to decrease transplant-related morbidity and mortality following alloSCT for B-CLL. 27 The results presented here demonstrate the potential role of alloSCT in the treatment of young patients with highrisk or chemorefractory B-CLL. The low relapse rate, as well as the lack of a significant correlation between relapse and pretransplant chemosensitivity or the dose-intensity of the preparative regimen, may all be the manifestations of a potent allogeneic GVL effect in B-CLL. Prospective collaborative studies are needed to determine the optimal use of alloSCT and to investigate the mechanisms of antitumor effects in B-CLL.
